Clotrimazole (Topical) interactions
Full monograph for Clotrimazole (Topical)Check it against another medicine
Medicines
533 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloride | Major | Metabolism | Coadministration with azole antifungal agents may significantly increase the plasma concentrations of amiodarone. The proposed mechanism is azole inhibition of… | 8 sources — open the full entry |
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Eplerenone | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme. | 1 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased… | 12 sources — open the full entry |
| Ivabradine | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by… | 9 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Neratinib Maleate | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily… | 7 sources — open the full entry |
| Ranolazine | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because… | 4 sources — open the full entry |
| Tacrolimus MonohydrateOralTopical | Major | Metabolism | Coadministration with clotrimazole may significantly increase the oral bioavailability of sirolimus and tacrolimus. The proposed mechanism is clotrimazole… | 5 sources — open the full entry |
| Valbenazine Tosylate | Major | Metabolism | Coadministration with a strong CYP450 3A4 inhibitor may increase the systemic exposure and risk of adverse effects of valbenazine, including somnolence and QT… | 4 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of alfuzosin, which is primarily metabolized by the isoenzyme… | 2 sources — open the full entry |
| Alprazolam | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines… | 28 sources — open the full entry |
| Amlodipine Besilate | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Metabolism · Unknown | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 40 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 59 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Metabolism · Unknown | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 40 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Metabolism · Unknown | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 40 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both… | 2 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these… | 5 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism · Unknown | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA…2 documented mechanisms | 19 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA… | 19 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Bortezomib | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes… | 1 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. | 5 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine. Orally administered bromocriptine is extensively… | 7 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide (Nasal Spray) | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic…2 documented mechanisms | 17 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Metabolism · Unknown | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic…2 documented mechanisms | 17 sources — open the full entry |
| Cabazitaxel | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. | 1 sources — open the full entry |
| Cabozantinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 2 sources — open the full entry |
| Cariprazine | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine… | 5 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is… | 2 sources — open the full entry |
| Cilostazol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 11 sources — open the full entry |
| Conjugated EstrogenCreamTablet | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Crizotinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Daclatasvir | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Darifenacin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Dasatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by… | 4 sources — open the full entry |
| Desogestrel | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 6 sources — open the full entry |
Conditions
Conditions in which Clotrimazole (Topical) needs care, as documented in this source.
Liver Diseases
ModerateAbnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches. The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.
1 source
- "Product Information. Mycelex (clotrimazole)." Bayer (2001):